United Therapeutics Corporation (NASDAQ:UTHR) Q4 2023 Earnings Call Transcript February 21, 2024 9:00 AM ET

Company Participants

Dewey Steadman - Head of Investor Relations

Martine Rothblatt - Chairperson & Chief Executive Officer

Michael Benkowitz - President & Chief Operating Officer

James Edgemond - Chief Financial Officer & Treasurer

Leigh Peterson - Executive Vice President of Product Development & Xenotransplantation

Conference Call Participants

Roanna Ruiz - Leerink Partners

Ash Verma - UBS

Jessica Fye - JPMorgan

Joseph Thome - TD Cowen

Hartaj Singh - Oppenheimer

Andreas Argyrides - Wedbush Securities

Operator

Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2023 Earnings Webcast. My name is David, and I will be your conference operator today. All participants on the call -- the webcast will be in a listen-only until the question-and-answer portion of the earnings call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Dewey Steadman, Head of Investor Relations at United Therapeutics.

Dewey Steadman

Thank you, Dave, and good morning. It's my pleasure to welcome you to the United Therapeutics Corporation's Fourth Quarter 2023 Earnings Webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update those forward-looking statements.

Today's remarks also may discuss the progress and results of clinical trials or other developments with respect to our products and these remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products are available on our website.

Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; Dr. Leigh Peterson, our Executive Vice President of Product Development and Xenotransplantation; and Pat Poisson, our Executive Vice President of Technical Operations.

Note that James and I will be participating in one-on-one meetings at the 2023 UBS European Healthcare conference on February 27th in London. Michael, James and I'll participate in a fireside chat and one-on-one meetings at the TD Cowen Healthcare conference on March 5 in Boston and Pat Poisson and I will participate in a fireside chat and one-on-one meetings at the Leerink Partners Global Biopharma Conference on March 12 in Miami.